{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,23]],"date-time":"2026-04-23T20:04:49Z","timestamp":1776974689471,"version":"3.51.4"},"reference-count":14,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,7,1]],"date-time":"2019-07-01T00:00:00Z","timestamp":1561939200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2019,7]]},"DOI":"10.1016\/j.clml.2019.03.028","type":"journal-article","created":{"date-parts":[[2019,4,4]],"date-time":"2019-04-04T10:58:50Z","timestamp":1554375530000},"page":"e377-e384","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":4,"title":["The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations"],"prefix":"10.1016","volume":"19","author":[{"given":"Teoman","family":"Soysal","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9568-0894","authenticated-orcid":false,"given":"Ahmet Emre","family":"Eskazan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Istemi","family":"Serin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sevil","family":"Sadri","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dilek","family":"Keskin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nurgul","family":"Ozgur Yurttas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Selin","family":"Berk","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isil","family":"Erdogan Ozunal","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ayse","family":"Salihoglu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muhlis Cem","family":"Ar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seniz","family":"Ongoren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zafer","family":"Baslar","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ugur","family":"Ozbek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yildiz","family":"Aydin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2019.03.028_bib1","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1182\/blood-2006-02-005686","article-title":"Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet","volume":"108","author":"Baccarani","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.028_bib2","doi-asserted-by":"crossref","first-page":"6041","DOI":"10.1200\/JCO.2009.25.0779","article-title":"Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet","volume":"27","author":"Baccarani","year":"2009","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.clml.2019.03.028_bib3","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1182\/blood-2013-05-501569","article-title":"European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013","volume":"122","author":"Baccarani","year":"2013","journal-title":"Blood"},{"issue":"suppl 2","key":"10.1016\/j.clml.2019.03.028_bib4","doi-asserted-by":"crossref","first-page":"S141","DOI":"10.1007\/s00277-015-2322-2","article-title":"A\u00a0review of the European LeukemiaNet recommendations for the management of CML","volume":"94","author":"Baccarani","year":"2015","journal-title":"Ann Hematol"},{"key":"10.1016\/j.clml.2019.03.028_bib5","doi-asserted-by":"crossref","first-page":"E206","DOI":"10.1002\/ajh.23816","article-title":"Do chronic myeloid leukemia patients with late \u201cwarning\u201d responses benefit from \u201cwatch and wait\u201d or switching therapy to a second generation tyrosine kinase inhibitor?","volume":"89","author":"Garc\u00eda-Guti\u00e9rrez","year":"2014","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.028_bib6","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1002\/ajh.23864","article-title":"ELN 2013 response status criteria: relevance for de novo imatinib chronic phase chronic myeloid leukemia patients?","volume":"90","author":"Etienne","year":"2015","journal-title":"Am J Hematol"},{"key":"10.1016\/j.clml.2019.03.028_bib7","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/bjh.13936","article-title":"Analysis of 2013 European LeukaemiaNet (ELN) responses in chronic phase CML across four frontline TKI modalities and impact on clinical outcomes","volume":"173","author":"Jain","year":"2016","journal-title":"Br J Haematol"},{"issue":"abstract 2792","key":"10.1016\/j.clml.2019.03.028_bib8","article-title":"Long-term outcome to first-line imatinib according to 2013 European LeukemiaNet response criteria: a GIMEMA CML WP analysis (abstract)","volume":"126","author":"Castagnetti","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.028_bib9","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1080\/17474086.2016.1231572","article-title":"Critical appraisal of European LeukemiaNet (ELN) 2013 recommendations for the management of chronic myeloid leukemia: is it early for a warning?","volume":"9","author":"Eskazan","year":"2016","journal-title":"Expert Rev Hematol"},{"key":"10.1016\/j.clml.2019.03.028_bib10","series-title":"WHO Classification of Tumors of Hematopoietic and Lymphoid Tissues","first-page":"32","article-title":"Chronic myelogenous leukemia BCR-ABL1 positive","author":"Vardiman","year":"2008"},{"key":"10.1016\/j.clml.2019.03.028_bib11","doi-asserted-by":"crossref","first-page":"5963","DOI":"10.1182\/blood-2011-10-383711","article-title":"Definitions, methodological and statistical issues for phase 3 clinical trials in chronic myeloid leukemia: a proposal by the European LeukemiaNet","volume":"119","author":"Guilhot","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.clml.2019.03.028_bib12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations","volume":"53","author":"Kaplan","year":"1958","journal-title":"J\u00a0Am Stat Assoc"},{"key":"10.1016\/j.clml.2019.03.028_bib13","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/j.leukres.2018.09.013","article-title":"Does switching to a second-generation tyrosine kinase inhibitor or increasing imatinib dose have long-term benefits in chronic myeloid leukemia patients with suboptimal responses under upfront standard-dose of imatinib?","volume":"74","author":"Eskazan","year":"2018","journal-title":"Leuk Res"},{"key":"10.1016\/j.clml.2019.03.028_bib14","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1016\/j.leukres.2018.06.002","article-title":"Comparative analyses of nilotinib versus high-dose imatinib versus sustained standard-dose imatinib in patients with chronic phase chronic myeloid leukemia following suboptimal molecular response to first-line imatinib","volume":"70","author":"Lee","year":"2018","journal-title":"Leuk Res"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018316161?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265018316161?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:32:31Z","timestamp":1761870751000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265018316161"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7]]},"references-count":14,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,7]]}},"alternative-id":["S2152265018316161"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.028","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Outcomes of Chronic Myeloid Leukemia Patients With Molecular Warning Responses During Imatinib Treatment According to the European LeukemiaNet 2013 Recommendations","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2019.03.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}